Scott Blumberg Sells 1,521 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 1,521 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $36,534.42. Following the completion of the sale, the chief financial officer directly owned 146,600 shares of the company’s stock, valued at approximately $3,521,332. This represents a 1.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total transaction of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Stock Up 0.0%

CeriBell stock traded up $0.01 on Tuesday, hitting $23.95. 243,381 shares of the stock traded hands, compared to its average volume of 457,237. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The business’s fifty day simple moving average is $19.77 and its 200 day simple moving average is $19.27. The firm has a market cap of $919.20 million, a P/E ratio of -13.61 and a beta of 0.81. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $25.33.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The business had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. As a group, sell-side analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. TimesSquare Capital Management LLC bought a new position in CeriBell during the 2nd quarter valued at about $15,182,000. Royce & Associates LP purchased a new stake in shares of CeriBell during the 4th quarter valued at about $11,695,000. KCM Capital Inc grew its stake in shares of CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after acquiring an additional 400,000 shares during the period. Landscape Capital Management L.L.C. bought a new stake in shares of CeriBell in the second quarter worth approximately $2,078,000. Finally, Kopp Family Office LLC purchased a new position in shares of CeriBell during the second quarter valued at approximately $672,000.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CBLL. BTIG Research upped their price target on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group lifted their target price on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Finally, Barclays upgraded shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and an average price target of $22.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.